澳大利亚Cyteph公司完成了CYT-101试验第一阶段的注册,这是一个针对经常性脑癌的现成T型细胞疗法。 Australian company Cyteph completes Phase I trial enrollment for CYT-101, an off-the-shelf T cell therapy targeting recurrent brain cancer.

澳大利亚生物技术公司Cyteph已经完成了CYT-101第一阶段临床试验的注册。 CYT-101是一个现成的T细胞疗法,针对常见血浆瘤多种形态中的细胞虫菌病毒抗原,即致命的脑癌。 Australian biotech company Cyteph has completed enrollment in a Phase I clinical trial for CYT-101, an off-the-shelf T cell therapy targeting cytomegalovirus antigens in recurrent glioblastoma multiforme, a deadly brain cancer. 该试验与Briz脑和脊柱以及Newro基金会一起进行,正在使用剂量降温方法评估治疗的安全性、可耐性和早期有效性。 The trial, conducted with Briz Brain & Spine and the Newro Foundation, is assessing the treatment’s safety, tolerability, and early effectiveness using a dose-escalation approach. 预期到2025年底取得结果。 Results are expected by the end of 2025. 这项疗法是根据对QIMR Berghofer的研究开发的,由澳大利亚的CUREAtor资助,旨在为选择有限的治疗病人提供精确的免疫疗法选择。 The therapy, developed from research at QIMR Berghofer and funded by Australia’s CUREator, aims to offer a precise immunotherapy option for patients with limited treatment choices.